



(51) International Patent Classification:

A61K 39/12 (2006.01)

A61K 39/00 (2006.01)

A61P 31/14 (2006.01)

(21) International Application Number:

PCT/GB2021/050602

(22) International Filing Date:

11 March 2021 (11.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2003670.3	13 March 2020 (13.03.2020)	GB
2006608.0	05 May 2020 (05.05.2020)	GB
2007062.9	13 May 2020 (13.05.2020)	GB
2009239.1	17 June 2020 (17.06.2020)	GB
2010569.8	09 July 2020 (09.07.2020)	GB
2016922.3	26 October 2020 (26.10.2020)	GB
2017284.7	30 October 2020 (30.10.2020)	GB
2017677.2	09 November 2020 (09.11.2020)	GB
2018410.7	23 November 2020 (23.11.2020)	GB
2018718.3	27 November 2020 (27.11.2020)	GB
2100034.4	04 January 2021 (04.01.2021)	GB

(71) Applicant: OXFORD UNIVERSITY INNOVATION

LIMITED [GB/GB]; Buxton Court, 3 West Way, Oxford
Oxfordshire OX2 0JB (GB).

(72) Inventors: GILBERT, Sarah C.; The Jenner Institute Lab-

oratories, University of Oxford, Old Road Campus Re-
search Building, Roosevelt Drive, Oxford Oxfordshire OX3
7DQ (GB). LAMBE, Teresa; The Jenner Institute Lab-
oratories, University of Oxford, Old Road Campus Re-
search Building, Roosevelt Drive, Oxford Oxfordshire OX3
7DQ (GB). SEBASTIAN, Sarah; Vaccitech Limited, The
Schrodinger Building, 2nd Floor, Heatley Road, The Oxford
Science Park, Oxford Oxfordshire OX4 4GE (GB).

(74) Agent: SCRIPT IP LIMITED et al.; Turnpike House, 18

Bridge Street, FROME Somerset BA11 1BB (GB).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: COMPOSITIONS AND METHODS FOR INDUCING AN IMMUNE RESPONSE




FIG. 1

(57) **Abstract:** The invention relates to a composition comprising a viral vector, the viral vector comprising nucleic acid having a polynucleotide sequence encoding the spike protein from the coronavirus SARS-CoV2, characterised in that said viral vector is an adenovirus based vector. The invention also relates to uses of such a composition and methods of treatment.

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*